nodes	percent_of_prediction	percent_of_DWPC	metapath
Imatinib—PDGFRB—sarcoma	0.185	0.372	CbGaD
Imatinib—PDGFRA—sarcoma	0.18	0.362	CbGaD
Imatinib—KIT—sarcoma	0.132	0.266	CbGaD
Imatinib—SLC47A1—Mitoxantrone—sarcoma	0.0802	0.313	CbGbCtD
Imatinib—ABCG2—Dactinomycin—sarcoma	0.0205	0.0798	CbGbCtD
Imatinib—ABCG2—Mitoxantrone—sarcoma	0.0183	0.0714	CbGbCtD
Imatinib—ABCG2—Vincristine—sarcoma	0.0126	0.0491	CbGbCtD
Imatinib—ABCG2—Etoposide—sarcoma	0.0115	0.045	CbGbCtD
Imatinib—PTGS1—Etoposide—sarcoma	0.0107	0.0416	CbGbCtD
Imatinib—CYP1A2—Dacarbazine—sarcoma	0.00973	0.038	CbGbCtD
Imatinib—CYP3A7—Vincristine—sarcoma	0.00931	0.0363	CbGbCtD
Imatinib—CYP3A7-CYP3A51P—Vincristine—sarcoma	0.00931	0.0363	CbGbCtD
Imatinib—CYP3A4—Thiotepa—sarcoma	0.0092	0.0359	CbGbCtD
Imatinib—ABCG2—Doxorubicin—sarcoma	0.00788	0.0307	CbGbCtD
Imatinib—ABCB1—Dactinomycin—sarcoma	0.00738	0.0288	CbGbCtD
Imatinib—CYP3A5—Vincristine—sarcoma	0.00698	0.0272	CbGbCtD
Imatinib—ABCB1—Mitoxantrone—sarcoma	0.0066	0.0258	CbGbCtD
Imatinib—CYP3A5—Etoposide—sarcoma	0.0064	0.025	CbGbCtD
Imatinib—CYP1A2—Etoposide—sarcoma	0.00476	0.0186	CbGbCtD
Imatinib—ABCB1—Vincristine—sarcoma	0.00454	0.0177	CbGbCtD
Imatinib—ABCB1—Etoposide—sarcoma	0.00416	0.0162	CbGbCtD
Imatinib—CYP3A4—Mitoxantrone—sarcoma	0.00396	0.0154	CbGbCtD
Imatinib—ABCB1—Doxorubicin—sarcoma	0.00284	0.0111	CbGbCtD
Imatinib—CYP3A4—Vincristine—sarcoma	0.00272	0.0106	CbGbCtD
Imatinib—CYP2D6—Doxorubicin—sarcoma	0.00268	0.0104	CbGbCtD
Imatinib—CYP3A4—Etoposide—sarcoma	0.00249	0.00973	CbGbCtD
Imatinib—CA3—pericardium—sarcoma	0.00246	0.0463	CbGeAlD
Imatinib—CYP3A4—Doxorubicin—sarcoma	0.0017	0.00664	CbGbCtD
Imatinib—CSF1R—periosteum—sarcoma	0.0016	0.0301	CbGeAlD
Imatinib—Ponatinib—TEK—sarcoma	0.00105	0.196	CrCbGaD
Imatinib—ABCA3—myometrium—sarcoma	0.000916	0.0173	CbGeAlD
Imatinib—CA2—periosteum—sarcoma	0.000859	0.0162	CbGeAlD
Imatinib—DDR1—myometrium—sarcoma	0.000845	0.0159	CbGeAlD
Imatinib—ABCA3—seminal vesicle—sarcoma	0.000828	0.0156	CbGeAlD
Imatinib—Nilotinib—TEK—sarcoma	0.000772	0.144	CrCbGaD
Imatinib—DDR1—seminal vesicle—sarcoma	0.000764	0.0144	CbGeAlD
Imatinib—PIP4K2C—mammary gland—sarcoma	0.000735	0.0139	CbGeAlD
Imatinib—Ponatinib—PDGFRA—sarcoma	0.000657	0.123	CrCbGaD
Imatinib—DDR1—smooth muscle tissue—sarcoma	0.000639	0.012	CbGeAlD
Imatinib—DDR1—cardiac atrium—sarcoma	0.000551	0.0104	CbGeAlD
Imatinib—DDR1—uterus—sarcoma	0.000548	0.0103	CbGeAlD
Imatinib—NTRK1—testis—sarcoma	0.000545	0.0103	CbGeAlD
Imatinib—Ponatinib—SRC—sarcoma	0.000544	0.102	CrCbGaD
Imatinib—PDGFRA—mammary gland—sarcoma	0.000539	0.0102	CbGeAlD
Imatinib—KIT—endothelium—sarcoma	0.000534	0.0101	CbGeAlD
Imatinib—PIP4K2C—myometrium—sarcoma	0.000522	0.00983	CbGeAlD
Imatinib—ABCA3—tendon—sarcoma	0.000521	0.00981	CbGeAlD
Imatinib—Ponatinib—KDR—sarcoma	0.000511	0.0955	CrCbGaD
Imatinib—CA3—myometrium—sarcoma	0.000498	0.00939	CbGeAlD
Imatinib—Nilotinib—PDGFRB—sarcoma	0.000498	0.093	CrCbGaD
Imatinib—Nilotinib—PDGFRA—sarcoma	0.000485	0.0906	CrCbGaD
Imatinib—Ponatinib—KIT—sarcoma	0.000482	0.0901	CrCbGaD
Imatinib—DDR1—tendon—sarcoma	0.00048	0.00905	CbGeAlD
Imatinib—CSF1R—mammary gland—sarcoma	0.000474	0.00894	CbGeAlD
Imatinib—PIP4K2C—seminal vesicle—sarcoma	0.000471	0.00888	CbGeAlD
Imatinib—HIPK4—testis—sarcoma	0.000436	0.00822	CbGeAlD
Imatinib—ABCA3—testis—sarcoma	0.000431	0.00812	CbGeAlD
Imatinib—KIT—mammary gland—sarcoma	0.000431	0.00812	CbGeAlD
Imatinib—PDGFRB—mammary gland—sarcoma	0.000421	0.00793	CbGeAlD
Imatinib—CA3—connective tissue—sarcoma	0.000412	0.00776	CbGeAlD
Imatinib—CA14—seminal vesicle—sarcoma	0.000409	0.0077	CbGeAlD
Imatinib—DDR1—testis—sarcoma	0.000398	0.0075	CbGeAlD
Imatinib—NQO2—myometrium—sarcoma	0.000383	0.00722	CbGeAlD
Imatinib—DDR1—liver—sarcoma	0.000376	0.00709	CbGeAlD
Imatinib—ABL1—mammary gland—sarcoma	0.000375	0.00707	CbGeAlD
Imatinib—PDGFRA—embryo—sarcoma	0.000368	0.00693	CbGeAlD
Imatinib—Nilotinib—KIT—sarcoma	0.000356	0.0665	CrCbGaD
Imatinib—NQO2—seminal vesicle—sarcoma	0.000346	0.00652	CbGeAlD
Imatinib—ALB—mammary gland—sarcoma	0.000346	0.00652	CbGeAlD
Imatinib—PIP4K2C—cardiac atrium—sarcoma	0.00034	0.00641	CbGeAlD
Imatinib—CSF1R—myometrium—sarcoma	0.000337	0.00634	CbGeAlD
Imatinib—PDGFRA—hematopoietic system—sarcoma	0.000328	0.00619	CbGeAlD
Imatinib—CA3—cardiac atrium—sarcoma	0.000325	0.00612	CbGeAlD
Imatinib—CSF1R—embryo—sarcoma	0.000324	0.0061	CbGeAlD
Imatinib—CA3—uterus—sarcoma	0.000323	0.00609	CbGeAlD
Imatinib—PDGFRA—connective tissue—sarcoma	0.000316	0.00596	CbGeAlD
Imatinib—ABL2—tendon—sarcoma	0.000313	0.00591	CbGeAlD
Imatinib—ABL1—Daunorubicin—Epirubicin—sarcoma	0.000313	0.173	CbGdCrCtD
Imatinib—ABL1—Idarubicin—Epirubicin—sarcoma	0.000313	0.173	CbGdCrCtD
Imatinib—ABL1—Doxorubicin—Epirubicin—sarcoma	0.000313	0.173	CbGdCrCtD
Imatinib—ABCA3—lymph node—sarcoma	0.000312	0.00589	CbGeAlD
Imatinib—SLC47A1—myometrium—sarcoma	0.000307	0.00579	CbGeAlD
Imatinib—KIT—myometrium—sarcoma	0.000306	0.00576	CbGeAlD
Imatinib—CSF1R—seminal vesicle—sarcoma	0.000304	0.00573	CbGeAlD
Imatinib—LCK—uterus—sarcoma	0.0003	0.00566	CbGeAlD
Imatinib—PDGFRB—myometrium—sarcoma	0.000298	0.00563	CbGeAlD
Imatinib—PIP4K2C—tendon—sarcoma	0.000297	0.00559	CbGeAlD
Imatinib—CA14—cardiac atrium—sarcoma	0.000295	0.00556	CbGeAlD
Imatinib—KIT—embryo—sarcoma	0.000294	0.00554	CbGeAlD
Imatinib—CA12—connective tissue—sarcoma	0.000292	0.0055	CbGeAlD
Imatinib—ABL1—Epirubicin—Doxorubicin—sarcoma	0.00029	0.16	CbGdCrCtD
Imatinib—ABL1—Idarubicin—Doxorubicin—sarcoma	0.00029	0.16	CbGdCrCtD
Imatinib—ABL1—Daunorubicin—Doxorubicin—sarcoma	0.00029	0.16	CbGdCrCtD
Imatinib—PDGFRA—smooth muscle tissue—sarcoma	0.000289	0.00545	CbGeAlD
Imatinib—CSF1R—hematopoietic system—sarcoma	0.000289	0.00545	CbGeAlD
Imatinib—DDR1—lymph node—sarcoma	0.000288	0.00543	CbGeAlD
Imatinib—PIP4K2C—bone marrow—sarcoma	0.000287	0.00541	CbGeAlD
Imatinib—PDGFRB—embryo—sarcoma	0.000287	0.00541	CbGeAlD
Imatinib—CA3—tendon—sarcoma	0.000283	0.00534	CbGeAlD
Imatinib—CSF1R—connective tissue—sarcoma	0.000278	0.00524	CbGeAlD
Imatinib—SLC47A1—seminal vesicle—sarcoma	0.000278	0.00523	CbGeAlD
Imatinib—KIT—seminal vesicle—sarcoma	0.000276	0.0052	CbGeAlD
Imatinib—CA3—bone marrow—sarcoma	0.000274	0.00517	CbGeAlD
Imatinib—CA9—tendon—sarcoma	0.000271	0.00511	CbGeAlD
Imatinib—PDGFRB—seminal vesicle—sarcoma	0.00027	0.00508	CbGeAlD
Imatinib—ABL1—myometrium—sarcoma	0.000266	0.00501	CbGeAlD
Imatinib—SLC47A1—hematopoietic system—sarcoma	0.000264	0.00497	CbGeAlD
Imatinib—KIT—hematopoietic system—sarcoma	0.000262	0.00495	CbGeAlD
Imatinib—ABL2—testis—sarcoma	0.00026	0.00489	CbGeAlD
Imatinib—CA14—tendon—sarcoma	0.000257	0.00485	CbGeAlD
Imatinib—PDGFRB—hematopoietic system—sarcoma	0.000256	0.00483	CbGeAlD
Imatinib—ABL1—embryo—sarcoma	0.000256	0.00482	CbGeAlD
Imatinib—LCK—bone marrow—sarcoma	0.000255	0.00481	CbGeAlD
Imatinib—CSF1R—smooth muscle tissue—sarcoma	0.000255	0.0048	CbGeAlD
Imatinib—KIT—connective tissue—sarcoma	0.000253	0.00476	CbGeAlD
Imatinib—CSF1R—skin of body—sarcoma	0.000251	0.00473	CbGeAlD
Imatinib—NQO2—cardiac atrium—sarcoma	0.00025	0.00471	CbGeAlD
Imatinib—NQO2—uterus—sarcoma	0.000249	0.00468	CbGeAlD
Imatinib—PDGFRA—uterus—sarcoma	0.000248	0.00467	CbGeAlD
Imatinib—PDGFRB—connective tissue—sarcoma	0.000247	0.00465	CbGeAlD
Imatinib—PIP4K2C—testis—sarcoma	0.000246	0.00463	CbGeAlD
Imatinib—ABL2—liver—sarcoma	0.000245	0.00462	CbGeAlD
Imatinib—PTGS1—endothelium—sarcoma	0.000245	0.00461	CbGeAlD
Imatinib—ORM1—hematopoietic system—sarcoma	0.00024	0.00453	CbGeAlD
Imatinib—ABL1—seminal vesicle—sarcoma	0.00024	0.00453	CbGeAlD
Imatinib—CA1—hematopoietic system—sarcoma	0.00024	0.00452	CbGeAlD
Imatinib—CA3—testis—sarcoma	0.000234	0.00442	CbGeAlD
Imatinib—PIP4K2C—liver—sarcoma	0.000232	0.00437	CbGeAlD
Imatinib—KIT—smooth muscle tissue—sarcoma	0.000231	0.00436	CbGeAlD
Imatinib—PDGFRA—lymphoid tissue—sarcoma	0.000231	0.00436	CbGeAlD
Imatinib—ABL1—hematopoietic system—sarcoma	0.000228	0.0043	CbGeAlD
Imatinib—KIT—skin of body—sarcoma	0.000228	0.0043	CbGeAlD
Imatinib—PDGFRB—smooth muscle tissue—sarcoma	0.000226	0.00425	CbGeAlD
Imatinib—CA9—testis—sarcoma	0.000224	0.00423	CbGeAlD
Imatinib—PDGFRB—skin of body—sarcoma	0.000223	0.0042	CbGeAlD
Imatinib—CA3—liver—sarcoma	0.000222	0.00418	CbGeAlD
Imatinib—ABL1—connective tissue—sarcoma	0.00022	0.00415	CbGeAlD
Imatinib—CSF1R—cardiac atrium—sarcoma	0.000219	0.00414	CbGeAlD
Imatinib—CSF1R—uterus—sarcoma	0.000218	0.00411	CbGeAlD
Imatinib—LCK—testis—sarcoma	0.000218	0.00411	CbGeAlD
Imatinib—NQO2—tendon—sarcoma	0.000218	0.0041	CbGeAlD
Imatinib—PDGFRA—tendon—sarcoma	0.000217	0.00409	CbGeAlD
Imatinib—CYP2C9—mammary gland—sarcoma	0.000216	0.00407	CbGeAlD
Imatinib—NQO2—bone marrow—sarcoma	0.000211	0.00398	CbGeAlD
Imatinib—LCK—liver—sarcoma	0.000206	0.00388	CbGeAlD
Imatinib—CSF1R—lymphoid tissue—sarcoma	0.000203	0.00383	CbGeAlD
Imatinib—CA14—liver—sarcoma	0.000201	0.00379	CbGeAlD
Imatinib—ABL1—smooth muscle tissue—sarcoma	0.000201	0.00379	CbGeAlD
Imatinib—SLC47A1—uterus—sarcoma	0.000199	0.00376	CbGeAlD
Imatinib—ABL1—skin of body—sarcoma	0.000199	0.00374	CbGeAlD
Imatinib—KIT—uterus—sarcoma	0.000198	0.00374	CbGeAlD
Imatinib—CYP3A7—liver—sarcoma	0.000197	0.00371	CbGeAlD
Imatinib—PDGFRB—cardiac atrium—sarcoma	0.000195	0.00367	CbGeAlD
Imatinib—PDGFRB—uterus—sarcoma	0.000194	0.00365	CbGeAlD
Imatinib—CSF1R—tendon—sarcoma	0.000191	0.0036	CbGeAlD
Imatinib—ABL2—lymph node—sarcoma	0.000188	0.00354	CbGeAlD
Imatinib—CSF1R—bone marrow—sarcoma	0.000185	0.00349	CbGeAlD
Imatinib—KIT—lymphoid tissue—sarcoma	0.000185	0.00348	CbGeAlD
Imatinib—PDGFRB—lymphoid tissue—sarcoma	0.00018	0.0034	CbGeAlD
Imatinib—NQO2—testis—sarcoma	0.00018	0.0034	CbGeAlD
Imatinib—PDGFRA—testis—sarcoma	0.00018	0.00339	CbGeAlD
Imatinib—PIP4K2C—lymph node—sarcoma	0.000178	0.00335	CbGeAlD
Imatinib—SLC47A1—tendon—sarcoma	0.000175	0.00329	CbGeAlD
Imatinib—CA2—embryo—sarcoma	0.000174	0.00328	CbGeAlD
Imatinib—ABL1—cardiac atrium—sarcoma	0.000173	0.00327	CbGeAlD
Imatinib—ABL1—uterus—sarcoma	0.000173	0.00325	CbGeAlD
Imatinib—NQO2—liver—sarcoma	0.00017	0.00321	CbGeAlD
Imatinib—PDGFRA—liver—sarcoma	0.00017	0.0032	CbGeAlD
Imatinib—CA3—lymph node—sarcoma	0.00017	0.0032	CbGeAlD
Imatinib—CYP2C19—hematopoietic system—sarcoma	0.00017	0.0032	CbGeAlD
Imatinib—PDGFRB—tendon—sarcoma	0.00017	0.0032	CbGeAlD
Imatinib—CA1—lymphoid tissue—sarcoma	0.000169	0.00318	CbGeAlD
Imatinib—KIT—bone marrow—sarcoma	0.000168	0.00317	CbGeAlD
Imatinib—ABCG2—myometrium—sarcoma	0.000168	0.00316	CbGeAlD
Imatinib—CYP3A7-CYP3A51P—liver—sarcoma	0.000167	0.00315	CbGeAlD
Imatinib—PDGFRB—bone marrow—sarcoma	0.000164	0.0031	CbGeAlD
Imatinib—CA2—seminal vesicle—sarcoma	0.000164	0.00308	CbGeAlD
Imatinib—ABL1—lymphoid tissue—sarcoma	0.000161	0.00303	CbGeAlD
Imatinib—CSF1R—testis—sarcoma	0.000158	0.00298	CbGeAlD
Imatinib—LCK—lymph node—sarcoma	0.000158	0.00298	CbGeAlD
Imatinib—CA2—hematopoietic system—sarcoma	0.000156	0.00293	CbGeAlD
Imatinib—ORM1—bone marrow—sarcoma	0.000154	0.0029	CbGeAlD
Imatinib—CA1—bone marrow—sarcoma	0.000154	0.0029	CbGeAlD
Imatinib—ABCG2—seminal vesicle—sarcoma	0.000152	0.00286	CbGeAlD
Imatinib—ABL1—tendon—sarcoma	0.000151	0.00285	CbGeAlD
Imatinib—CA2—connective tissue—sarcoma	0.00015	0.00282	CbGeAlD
Imatinib—CSF1R—liver—sarcoma	0.00015	0.00282	CbGeAlD
Imatinib—ABL1—bone marrow—sarcoma	0.000146	0.00276	CbGeAlD
Imatinib—SLC47A1—testis—sarcoma	0.000145	0.00273	CbGeAlD
Imatinib—KIT—testis—sarcoma	0.000144	0.00271	CbGeAlD
Imatinib—PDGFRB—testis—sarcoma	0.00014	0.00265	CbGeAlD
Imatinib—CYP1A2—hematopoietic system—sarcoma	0.000139	0.00261	CbGeAlD
Imatinib—CA2—smooth muscle tissue—sarcoma	0.000137	0.00258	CbGeAlD
Imatinib—SLC47A1—liver—sarcoma	0.000137	0.00258	CbGeAlD
Imatinib—KIT—liver—sarcoma	0.000136	0.00256	CbGeAlD
Imatinib—CA2—skin of body—sarcoma	0.000135	0.00255	CbGeAlD
Imatinib—CYP3A5—hematopoietic system—sarcoma	0.000134	0.00252	CbGeAlD
Imatinib—PDGFRB—liver—sarcoma	0.000133	0.0025	CbGeAlD
Imatinib—CYP2C9—hematopoietic system—sarcoma	0.000132	0.00248	CbGeAlD
Imatinib—NQO2—lymph node—sarcoma	0.000131	0.00246	CbGeAlD
Imatinib—PDGFRA—lymph node—sarcoma	0.00013	0.00246	CbGeAlD
Imatinib—PTGS1—seminal vesicle—sarcoma	0.000126	0.00238	CbGeAlD
Imatinib—ABL1—testis—sarcoma	0.000125	0.00236	CbGeAlD
Imatinib—ORM1—liver—sarcoma	0.000125	0.00235	CbGeAlD
Imatinib—CA1—liver—sarcoma	0.000124	0.00234	CbGeAlD
Imatinib—PTGS1—hematopoietic system—sarcoma	0.00012	0.00226	CbGeAlD
Imatinib—ABL1—liver—sarcoma	0.000118	0.00223	CbGeAlD
Imatinib—CA2—cardiac atrium—sarcoma	0.000118	0.00223	CbGeAlD
Imatinib—PTGS1—connective tissue—sarcoma	0.000116	0.00218	CbGeAlD
Imatinib—ALB—testis—sarcoma	0.000116	0.00218	CbGeAlD
Imatinib—CSF1R—lymph node—sarcoma	0.000115	0.00216	CbGeAlD
Imatinib—SLC22A1—liver—sarcoma	0.000114	0.00215	CbGeAlD
Imatinib—CA2—lymphoid tissue—sarcoma	0.00011	0.00206	CbGeAlD
Imatinib—ALB—liver—sarcoma	0.000109	0.00206	CbGeAlD
Imatinib—ABCG2—uterus—sarcoma	0.000109	0.00205	CbGeAlD
Imatinib—PTGS1—smooth muscle tissue—sarcoma	0.000106	0.00199	CbGeAlD
Imatinib—SLC47A1—lymph node—sarcoma	0.000105	0.00198	CbGeAlD
Imatinib—PTGS1—skin of body—sarcoma	0.000104	0.00197	CbGeAlD
Imatinib—KIT—lymph node—sarcoma	0.000104	0.00196	CbGeAlD
Imatinib—CA2—tendon—sarcoma	0.000103	0.00194	CbGeAlD
Imatinib—PDGFRB—lymph node—sarcoma	0.000102	0.00192	CbGeAlD
Imatinib—CYP3A4—hematopoietic system—sarcoma	0.0001	0.00189	CbGeAlD
Imatinib—CA2—bone marrow—sarcoma	9.97e-05	0.00188	CbGeAlD
Imatinib—CYP2D6—hematopoietic system—sarcoma	9.87e-05	0.00186	CbGeAlD
Imatinib—ORM1—lymph node—sarcoma	9.55e-05	0.0018	CbGeAlD
Imatinib—CA1—lymph node—sarcoma	9.53e-05	0.0018	CbGeAlD
Imatinib—ABCG2—bone marrow—sarcoma	9.23e-05	0.00174	CbGeAlD
Imatinib—PTGS1—cardiac atrium—sarcoma	9.12e-05	0.00172	CbGeAlD
Imatinib—PTGS1—uterus—sarcoma	9.07e-05	0.00171	CbGeAlD
Imatinib—ABL1—lymph node—sarcoma	9.07e-05	0.00171	CbGeAlD
Imatinib—CYP2C19—liver—sarcoma	8.79e-05	0.00166	CbGeAlD
Imatinib—CA2—testis—sarcoma	8.52e-05	0.00161	CbGeAlD
Imatinib—ALB—lymph node—sarcoma	8.37e-05	0.00158	CbGeAlD
Imatinib—ABCB1—myometrium—sarcoma	8.27e-05	0.00156	CbGeAlD
Imatinib—CA2—liver—sarcoma	8.06e-05	0.00152	CbGeAlD
Imatinib—ABCB1—embryo—sarcoma	7.96e-05	0.0015	CbGeAlD
Imatinib—PTGS1—tendon—sarcoma	7.95e-05	0.0015	CbGeAlD
Imatinib—ABCG2—testis—sarcoma	7.89e-05	0.00149	CbGeAlD
Imatinib—ABCB1—seminal vesicle—sarcoma	7.47e-05	0.00141	CbGeAlD
Imatinib—ABCG2—liver—sarcoma	7.46e-05	0.00141	CbGeAlD
Imatinib—CYP1A2—liver—sarcoma	7.18e-05	0.00135	CbGeAlD
Imatinib—ABCB1—hematopoietic system—sarcoma	7.1e-05	0.00134	CbGeAlD
Imatinib—CYP3A5—liver—sarcoma	6.93e-05	0.00131	CbGeAlD
Imatinib—CYP2C9—liver—sarcoma	6.82e-05	0.00128	CbGeAlD
Imatinib—PTGS1—testis—sarcoma	6.58e-05	0.00124	CbGeAlD
Imatinib—CA2—lymph node—sarcoma	6.18e-05	0.00116	CbGeAlD
Imatinib—ABCG2—lymph node—sarcoma	5.72e-05	0.00108	CbGeAlD
Imatinib—CYP2D6—testis—sarcoma	5.41e-05	0.00102	CbGeAlD
Imatinib—ABCB1—uterus—sarcoma	5.37e-05	0.00101	CbGeAlD
Imatinib—Infestation NOS—Epirubicin—sarcoma	5.25e-05	0.000504	CcSEcCtD
Imatinib—Infestation—Epirubicin—sarcoma	5.25e-05	0.000504	CcSEcCtD
Imatinib—Vomiting—Dactinomycin—sarcoma	5.25e-05	0.000504	CcSEcCtD
Imatinib—Rash—Thiotepa—sarcoma	5.24e-05	0.000503	CcSEcCtD
Imatinib—Dermatitis—Thiotepa—sarcoma	5.24e-05	0.000503	CcSEcCtD
Imatinib—Headache—Thiotepa—sarcoma	5.21e-05	0.0005	CcSEcCtD
Imatinib—Stevens-Johnson syndrome—Epirubicin—sarcoma	5.2e-05	0.000499	CcSEcCtD
Imatinib—Rash—Dactinomycin—sarcoma	5.2e-05	0.000499	CcSEcCtD
Imatinib—CYP3A4—liver—sarcoma	5.2e-05	0.00098	CbGeAlD
Imatinib—Decreased appetite—Etoposide—sarcoma	5.19e-05	0.000498	CcSEcCtD
Imatinib—Pancytopenia—Doxorubicin—sarcoma	5.17e-05	0.000497	CcSEcCtD
Imatinib—Renal failure—Epirubicin—sarcoma	5.16e-05	0.000495	CcSEcCtD
Imatinib—Gastrointestinal disorder—Etoposide—sarcoma	5.15e-05	0.000495	CcSEcCtD
Imatinib—Asthenia—Mitoxantrone—sarcoma	5.15e-05	0.000494	CcSEcCtD
Imatinib—Fatigue—Etoposide—sarcoma	5.15e-05	0.000494	CcSEcCtD
Imatinib—Neuropathy peripheral—Epirubicin—sarcoma	5.14e-05	0.000494	CcSEcCtD
Imatinib—CYP2D6—liver—sarcoma	5.12e-05	0.000964	CbGeAlD
Imatinib—Stomatitis—Epirubicin—sarcoma	5.11e-05	0.000491	CcSEcCtD
Imatinib—Jaundice—Epirubicin—sarcoma	5.11e-05	0.000491	CcSEcCtD
Imatinib—Constipation—Etoposide—sarcoma	5.11e-05	0.00049	CcSEcCtD
Imatinib—Pain—Etoposide—sarcoma	5.11e-05	0.00049	CcSEcCtD
Imatinib—Conjunctivitis—Epirubicin—sarcoma	5.1e-05	0.00049	CcSEcCtD
Imatinib—Urinary tract infection—Epirubicin—sarcoma	5.1e-05	0.00049	CcSEcCtD
Imatinib—Neutropenia—Doxorubicin—sarcoma	5.09e-05	0.000489	CcSEcCtD
Imatinib—Upper respiratory tract infection—Doxorubicin—sarcoma	5.06e-05	0.000486	CcSEcCtD
Imatinib—Diarrhoea—Vincristine—sarcoma	5.04e-05	0.000484	CcSEcCtD
Imatinib—Sweating—Epirubicin—sarcoma	5.03e-05	0.000483	CcSEcCtD
Imatinib—Pollakiuria—Doxorubicin—sarcoma	5.03e-05	0.000483	CcSEcCtD
Imatinib—Haematuria—Epirubicin—sarcoma	5e-05	0.00048	CcSEcCtD
Imatinib—ABCB1—lymphoid tissue—sarcoma	5e-05	0.000942	CbGeAlD
Imatinib—Photosensitivity reaction—Doxorubicin—sarcoma	4.97e-05	0.000477	CcSEcCtD
Imatinib—Hepatobiliary disease—Epirubicin—sarcoma	4.96e-05	0.000476	CcSEcCtD
Imatinib—Weight increased—Doxorubicin—sarcoma	4.96e-05	0.000476	CcSEcCtD
Imatinib—Epistaxis—Epirubicin—sarcoma	4.95e-05	0.000475	CcSEcCtD
Imatinib—Nausea—Thiotepa—sarcoma	4.94e-05	0.000474	CcSEcCtD
Imatinib—Weight decreased—Doxorubicin—sarcoma	4.93e-05	0.000473	CcSEcCtD
Imatinib—Sinusitis—Epirubicin—sarcoma	4.92e-05	0.000473	CcSEcCtD
Imatinib—Feeling abnormal—Etoposide—sarcoma	4.92e-05	0.000472	CcSEcCtD
Imatinib—Hyperglycaemia—Doxorubicin—sarcoma	4.91e-05	0.000472	CcSEcCtD
Imatinib—Diarrhoea—Mitoxantrone—sarcoma	4.91e-05	0.000472	CcSEcCtD
Imatinib—Nausea—Dactinomycin—sarcoma	4.9e-05	0.00047	CcSEcCtD
Imatinib—Agranulocytosis—Epirubicin—sarcoma	4.9e-05	0.00047	CcSEcCtD
Imatinib—Pneumonia—Doxorubicin—sarcoma	4.88e-05	0.000469	CcSEcCtD
Imatinib—Gastrointestinal pain—Etoposide—sarcoma	4.88e-05	0.000469	CcSEcCtD
Imatinib—Dizziness—Vincristine—sarcoma	4.87e-05	0.000468	CcSEcCtD
Imatinib—Infestation NOS—Doxorubicin—sarcoma	4.86e-05	0.000466	CcSEcCtD
Imatinib—Infestation—Doxorubicin—sarcoma	4.86e-05	0.000466	CcSEcCtD
Imatinib—Stevens-Johnson syndrome—Doxorubicin—sarcoma	4.81e-05	0.000462	CcSEcCtD
Imatinib—Renal failure—Doxorubicin—sarcoma	4.77e-05	0.000458	CcSEcCtD
Imatinib—PTGS1—lymph node—sarcoma	4.77e-05	0.000899	CbGeAlD
Imatinib—Neuropathy peripheral—Doxorubicin—sarcoma	4.76e-05	0.000457	CcSEcCtD
Imatinib—Urticaria—Etoposide—sarcoma	4.74e-05	0.000455	CcSEcCtD
Imatinib—Haemoglobin—Epirubicin—sarcoma	4.73e-05	0.000455	CcSEcCtD
Imatinib—Stomatitis—Doxorubicin—sarcoma	4.73e-05	0.000454	CcSEcCtD
Imatinib—Jaundice—Doxorubicin—sarcoma	4.73e-05	0.000454	CcSEcCtD
Imatinib—Rhinitis—Epirubicin—sarcoma	4.72e-05	0.000453	CcSEcCtD
Imatinib—Body temperature increased—Etoposide—sarcoma	4.72e-05	0.000453	CcSEcCtD
Imatinib—Abdominal pain—Etoposide—sarcoma	4.72e-05	0.000453	CcSEcCtD
Imatinib—Conjunctivitis—Doxorubicin—sarcoma	4.72e-05	0.000453	CcSEcCtD
Imatinib—Urinary tract infection—Doxorubicin—sarcoma	4.72e-05	0.000453	CcSEcCtD
Imatinib—Haemorrhage—Epirubicin—sarcoma	4.71e-05	0.000452	CcSEcCtD
Imatinib—Hepatitis—Epirubicin—sarcoma	4.71e-05	0.000452	CcSEcCtD
Imatinib—Hypoaesthesia—Epirubicin—sarcoma	4.69e-05	0.00045	CcSEcCtD
Imatinib—Vomiting—Vincristine—sarcoma	4.69e-05	0.00045	CcSEcCtD
Imatinib—Pharyngitis—Epirubicin—sarcoma	4.68e-05	0.000449	CcSEcCtD
Imatinib—Sweating—Doxorubicin—sarcoma	4.65e-05	0.000447	CcSEcCtD
Imatinib—Urinary tract disorder—Epirubicin—sarcoma	4.65e-05	0.000447	CcSEcCtD
Imatinib—Rash—Vincristine—sarcoma	4.65e-05	0.000446	CcSEcCtD
Imatinib—Dermatitis—Vincristine—sarcoma	4.64e-05	0.000446	CcSEcCtD
Imatinib—Oedema peripheral—Epirubicin—sarcoma	4.64e-05	0.000446	CcSEcCtD
Imatinib—Haematuria—Doxorubicin—sarcoma	4.63e-05	0.000444	CcSEcCtD
Imatinib—Connective tissue disorder—Epirubicin—sarcoma	4.63e-05	0.000444	CcSEcCtD
Imatinib—Urethral disorder—Epirubicin—sarcoma	4.62e-05	0.000443	CcSEcCtD
Imatinib—Headache—Vincristine—sarcoma	4.62e-05	0.000443	CcSEcCtD
Imatinib—Hepatobiliary disease—Doxorubicin—sarcoma	4.59e-05	0.000441	CcSEcCtD
Imatinib—Epistaxis—Doxorubicin—sarcoma	4.58e-05	0.00044	CcSEcCtD
Imatinib—Vomiting—Mitoxantrone—sarcoma	4.56e-05	0.000438	CcSEcCtD
Imatinib—Sinusitis—Doxorubicin—sarcoma	4.56e-05	0.000437	CcSEcCtD
Imatinib—ABCB1—bone marrow—sarcoma	4.55e-05	0.000858	CbGeAlD
Imatinib—Agranulocytosis—Doxorubicin—sarcoma	4.53e-05	0.000435	CcSEcCtD
Imatinib—Rash—Mitoxantrone—sarcoma	4.53e-05	0.000435	CcSEcCtD
Imatinib—Dermatitis—Mitoxantrone—sarcoma	4.52e-05	0.000434	CcSEcCtD
Imatinib—Headache—Mitoxantrone—sarcoma	4.5e-05	0.000432	CcSEcCtD
Imatinib—Erythema multiforme—Epirubicin—sarcoma	4.45e-05	0.000428	CcSEcCtD
Imatinib—Eye disorder—Epirubicin—sarcoma	4.4e-05	0.000423	CcSEcCtD
Imatinib—Hypersensitivity—Etoposide—sarcoma	4.4e-05	0.000422	CcSEcCtD
Imatinib—Tinnitus—Epirubicin—sarcoma	4.39e-05	0.000422	CcSEcCtD
Imatinib—Haemoglobin—Doxorubicin—sarcoma	4.38e-05	0.000421	CcSEcCtD
Imatinib—Nausea—Vincristine—sarcoma	4.38e-05	0.00042	CcSEcCtD
Imatinib—Cardiac disorder—Epirubicin—sarcoma	4.37e-05	0.00042	CcSEcCtD
Imatinib—Flushing—Epirubicin—sarcoma	4.37e-05	0.00042	CcSEcCtD
Imatinib—Rhinitis—Doxorubicin—sarcoma	4.37e-05	0.00042	CcSEcCtD
Imatinib—Haemorrhage—Doxorubicin—sarcoma	4.36e-05	0.000418	CcSEcCtD
Imatinib—Hepatitis—Doxorubicin—sarcoma	4.36e-05	0.000418	CcSEcCtD
Imatinib—Hypoaesthesia—Doxorubicin—sarcoma	4.34e-05	0.000416	CcSEcCtD
Imatinib—Pharyngitis—Doxorubicin—sarcoma	4.33e-05	0.000415	CcSEcCtD
Imatinib—Urinary tract disorder—Doxorubicin—sarcoma	4.3e-05	0.000413	CcSEcCtD
Imatinib—Oedema peripheral—Doxorubicin—sarcoma	4.29e-05	0.000412	CcSEcCtD
Imatinib—Asthenia—Etoposide—sarcoma	4.28e-05	0.000411	CcSEcCtD
Imatinib—Connective tissue disorder—Doxorubicin—sarcoma	4.28e-05	0.000411	CcSEcCtD
Imatinib—Angiopathy—Epirubicin—sarcoma	4.27e-05	0.00041	CcSEcCtD
Imatinib—Urethral disorder—Doxorubicin—sarcoma	4.27e-05	0.00041	CcSEcCtD
Imatinib—Nausea—Mitoxantrone—sarcoma	4.26e-05	0.000409	CcSEcCtD
Imatinib—Immune system disorder—Epirubicin—sarcoma	4.25e-05	0.000409	CcSEcCtD
Imatinib—Mediastinal disorder—Epirubicin—sarcoma	4.25e-05	0.000408	CcSEcCtD
Imatinib—Chills—Epirubicin—sarcoma	4.23e-05	0.000406	CcSEcCtD
Imatinib—Pruritus—Etoposide—sarcoma	4.22e-05	0.000406	CcSEcCtD
Imatinib—Arrhythmia—Epirubicin—sarcoma	4.21e-05	0.000404	CcSEcCtD
Imatinib—Alopecia—Epirubicin—sarcoma	4.16e-05	0.0004	CcSEcCtD
Imatinib—Mental disorder—Epirubicin—sarcoma	4.13e-05	0.000396	CcSEcCtD
Imatinib—Erythema multiforme—Doxorubicin—sarcoma	4.12e-05	0.000396	CcSEcCtD
Imatinib—Malnutrition—Epirubicin—sarcoma	4.1e-05	0.000394	CcSEcCtD
Imatinib—Erythema—Epirubicin—sarcoma	4.1e-05	0.000394	CcSEcCtD
Imatinib—Diarrhoea—Etoposide—sarcoma	4.09e-05	0.000392	CcSEcCtD
Imatinib—Eye disorder—Doxorubicin—sarcoma	4.07e-05	0.000391	CcSEcCtD
Imatinib—Tinnitus—Doxorubicin—sarcoma	4.06e-05	0.00039	CcSEcCtD
Imatinib—Cardiac disorder—Doxorubicin—sarcoma	4.05e-05	0.000388	CcSEcCtD
Imatinib—Flushing—Doxorubicin—sarcoma	4.05e-05	0.000388	CcSEcCtD
Imatinib—Flatulence—Epirubicin—sarcoma	4.04e-05	0.000388	CcSEcCtD
Imatinib—Dysgeusia—Epirubicin—sarcoma	4.02e-05	0.000386	CcSEcCtD
Imatinib—Back pain—Epirubicin—sarcoma	3.97e-05	0.000381	CcSEcCtD
Imatinib—Angiopathy—Doxorubicin—sarcoma	3.95e-05	0.00038	CcSEcCtD
Imatinib—Dizziness—Etoposide—sarcoma	3.95e-05	0.000379	CcSEcCtD
Imatinib—Muscle spasms—Epirubicin—sarcoma	3.94e-05	0.000379	CcSEcCtD
Imatinib—Immune system disorder—Doxorubicin—sarcoma	3.94e-05	0.000378	CcSEcCtD
Imatinib—Mediastinal disorder—Doxorubicin—sarcoma	3.93e-05	0.000377	CcSEcCtD
Imatinib—Chills—Doxorubicin—sarcoma	3.91e-05	0.000375	CcSEcCtD
Imatinib—Arrhythmia—Doxorubicin—sarcoma	3.89e-05	0.000374	CcSEcCtD
Imatinib—ABCB1—testis—sarcoma	3.89e-05	0.000734	CbGeAlD
Imatinib—Vision blurred—Epirubicin—sarcoma	3.86e-05	0.000371	CcSEcCtD
Imatinib—Alopecia—Doxorubicin—sarcoma	3.85e-05	0.00037	CcSEcCtD
Imatinib—Mental disorder—Doxorubicin—sarcoma	3.82e-05	0.000367	CcSEcCtD
Imatinib—Ill-defined disorder—Epirubicin—sarcoma	3.8e-05	0.000365	CcSEcCtD
Imatinib—Vomiting—Etoposide—sarcoma	3.8e-05	0.000364	CcSEcCtD
Imatinib—Malnutrition—Doxorubicin—sarcoma	3.79e-05	0.000364	CcSEcCtD
Imatinib—Erythema—Doxorubicin—sarcoma	3.79e-05	0.000364	CcSEcCtD
Imatinib—Anaemia—Epirubicin—sarcoma	3.79e-05	0.000364	CcSEcCtD
Imatinib—Rash—Etoposide—sarcoma	3.76e-05	0.000361	CcSEcCtD
Imatinib—Dermatitis—Etoposide—sarcoma	3.76e-05	0.000361	CcSEcCtD
Imatinib—Headache—Etoposide—sarcoma	3.74e-05	0.000359	CcSEcCtD
Imatinib—Flatulence—Doxorubicin—sarcoma	3.74e-05	0.000359	CcSEcCtD
Imatinib—Dysgeusia—Doxorubicin—sarcoma	3.72e-05	0.000357	CcSEcCtD
Imatinib—Malaise—Epirubicin—sarcoma	3.7e-05	0.000355	CcSEcCtD
Imatinib—Vertigo—Epirubicin—sarcoma	3.68e-05	0.000354	CcSEcCtD
Imatinib—ABCB1—liver—sarcoma	3.68e-05	0.000694	CbGeAlD
Imatinib—Syncope—Epirubicin—sarcoma	3.68e-05	0.000353	CcSEcCtD
Imatinib—Leukopenia—Epirubicin—sarcoma	3.67e-05	0.000352	CcSEcCtD
Imatinib—Back pain—Doxorubicin—sarcoma	3.67e-05	0.000352	CcSEcCtD
Imatinib—Muscle spasms—Doxorubicin—sarcoma	3.65e-05	0.00035	CcSEcCtD
Imatinib—Palpitations—Epirubicin—sarcoma	3.62e-05	0.000348	CcSEcCtD
Imatinib—Loss of consciousness—Epirubicin—sarcoma	3.6e-05	0.000346	CcSEcCtD
Imatinib—Cough—Epirubicin—sarcoma	3.58e-05	0.000344	CcSEcCtD
Imatinib—Vision blurred—Doxorubicin—sarcoma	3.58e-05	0.000343	CcSEcCtD
Imatinib—Convulsion—Epirubicin—sarcoma	3.55e-05	0.000341	CcSEcCtD
Imatinib—Nausea—Etoposide—sarcoma	3.55e-05	0.00034	CcSEcCtD
Imatinib—Hypertension—Epirubicin—sarcoma	3.54e-05	0.00034	CcSEcCtD
Imatinib—Ill-defined disorder—Doxorubicin—sarcoma	3.52e-05	0.000338	CcSEcCtD
Imatinib—Anaemia—Doxorubicin—sarcoma	3.51e-05	0.000337	CcSEcCtD
Imatinib—Myalgia—Epirubicin—sarcoma	3.49e-05	0.000335	CcSEcCtD
Imatinib—Chest pain—Epirubicin—sarcoma	3.49e-05	0.000335	CcSEcCtD
Imatinib—Arthralgia—Epirubicin—sarcoma	3.49e-05	0.000335	CcSEcCtD
Imatinib—Anxiety—Epirubicin—sarcoma	3.48e-05	0.000334	CcSEcCtD
Imatinib—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—sarcoma	3.47e-05	0.000333	CcSEcCtD
Imatinib—Discomfort—Epirubicin—sarcoma	3.45e-05	0.000331	CcSEcCtD
Imatinib—Malaise—Doxorubicin—sarcoma	3.42e-05	0.000329	CcSEcCtD
Imatinib—Dry mouth—Epirubicin—sarcoma	3.41e-05	0.000328	CcSEcCtD
Imatinib—Vertigo—Doxorubicin—sarcoma	3.41e-05	0.000327	CcSEcCtD
Imatinib—Syncope—Doxorubicin—sarcoma	3.4e-05	0.000327	CcSEcCtD
Imatinib—Leukopenia—Doxorubicin—sarcoma	3.4e-05	0.000326	CcSEcCtD
Imatinib—Confusional state—Epirubicin—sarcoma	3.37e-05	0.000324	CcSEcCtD
Imatinib—Palpitations—Doxorubicin—sarcoma	3.35e-05	0.000322	CcSEcCtD
Imatinib—Oedema—Epirubicin—sarcoma	3.35e-05	0.000321	CcSEcCtD
Imatinib—Anaphylactic shock—Epirubicin—sarcoma	3.35e-05	0.000321	CcSEcCtD
Imatinib—Loss of consciousness—Doxorubicin—sarcoma	3.33e-05	0.00032	CcSEcCtD
Imatinib—Infection—Epirubicin—sarcoma	3.32e-05	0.000319	CcSEcCtD
Imatinib—Cough—Doxorubicin—sarcoma	3.31e-05	0.000318	CcSEcCtD
Imatinib—Shock—Epirubicin—sarcoma	3.29e-05	0.000316	CcSEcCtD
Imatinib—Convulsion—Doxorubicin—sarcoma	3.29e-05	0.000316	CcSEcCtD
Imatinib—Nervous system disorder—Epirubicin—sarcoma	3.28e-05	0.000315	CcSEcCtD
Imatinib—Thrombocytopenia—Epirubicin—sarcoma	3.28e-05	0.000315	CcSEcCtD
Imatinib—Hypertension—Doxorubicin—sarcoma	3.28e-05	0.000315	CcSEcCtD
Imatinib—Tachycardia—Epirubicin—sarcoma	3.27e-05	0.000314	CcSEcCtD
Imatinib—Skin disorder—Epirubicin—sarcoma	3.25e-05	0.000312	CcSEcCtD
Imatinib—Hyperhidrosis—Epirubicin—sarcoma	3.24e-05	0.000311	CcSEcCtD
Imatinib—Arthralgia—Doxorubicin—sarcoma	3.23e-05	0.00031	CcSEcCtD
Imatinib—Chest pain—Doxorubicin—sarcoma	3.23e-05	0.00031	CcSEcCtD
Imatinib—Myalgia—Doxorubicin—sarcoma	3.23e-05	0.00031	CcSEcCtD
Imatinib—Anxiety—Doxorubicin—sarcoma	3.22e-05	0.000309	CcSEcCtD
Imatinib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—sarcoma	3.21e-05	0.000308	CcSEcCtD
Imatinib—Discomfort—Doxorubicin—sarcoma	3.19e-05	0.000306	CcSEcCtD
Imatinib—Anorexia—Epirubicin—sarcoma	3.19e-05	0.000306	CcSEcCtD
Imatinib—Dry mouth—Doxorubicin—sarcoma	3.16e-05	0.000303	CcSEcCtD
Imatinib—Hypotension—Epirubicin—sarcoma	3.13e-05	0.0003	CcSEcCtD
Imatinib—Confusional state—Doxorubicin—sarcoma	3.12e-05	0.0003	CcSEcCtD
Imatinib—Oedema—Doxorubicin—sarcoma	3.1e-05	0.000297	CcSEcCtD
Imatinib—Anaphylactic shock—Doxorubicin—sarcoma	3.1e-05	0.000297	CcSEcCtD
Imatinib—Infection—Doxorubicin—sarcoma	3.08e-05	0.000295	CcSEcCtD
Imatinib—Musculoskeletal discomfort—Epirubicin—sarcoma	3.05e-05	0.000293	CcSEcCtD
Imatinib—Shock—Doxorubicin—sarcoma	3.05e-05	0.000293	CcSEcCtD
Imatinib—Nervous system disorder—Doxorubicin—sarcoma	3.04e-05	0.000292	CcSEcCtD
Imatinib—Thrombocytopenia—Doxorubicin—sarcoma	3.03e-05	0.000291	CcSEcCtD
Imatinib—Insomnia—Epirubicin—sarcoma	3.03e-05	0.000291	CcSEcCtD
Imatinib—Tachycardia—Doxorubicin—sarcoma	3.02e-05	0.00029	CcSEcCtD
Imatinib—Skin disorder—Doxorubicin—sarcoma	3.01e-05	0.000289	CcSEcCtD
Imatinib—Paraesthesia—Epirubicin—sarcoma	3.01e-05	0.000289	CcSEcCtD
Imatinib—Hyperhidrosis—Doxorubicin—sarcoma	2.99e-05	0.000287	CcSEcCtD
Imatinib—Dyspnoea—Epirubicin—sarcoma	2.98e-05	0.000286	CcSEcCtD
Imatinib—Somnolence—Epirubicin—sarcoma	2.98e-05	0.000286	CcSEcCtD
Imatinib—Anorexia—Doxorubicin—sarcoma	2.95e-05	0.000283	CcSEcCtD
Imatinib—Dyspepsia—Epirubicin—sarcoma	2.95e-05	0.000283	CcSEcCtD
Imatinib—Decreased appetite—Epirubicin—sarcoma	2.91e-05	0.000279	CcSEcCtD
Imatinib—Hypotension—Doxorubicin—sarcoma	2.89e-05	0.000278	CcSEcCtD
Imatinib—Gastrointestinal disorder—Epirubicin—sarcoma	2.89e-05	0.000277	CcSEcCtD
Imatinib—Fatigue—Epirubicin—sarcoma	2.89e-05	0.000277	CcSEcCtD
Imatinib—Pain—Epirubicin—sarcoma	2.86e-05	0.000275	CcSEcCtD
Imatinib—Constipation—Epirubicin—sarcoma	2.86e-05	0.000275	CcSEcCtD
Imatinib—ABCB1—lymph node—sarcoma	2.82e-05	0.000532	CbGeAlD
Imatinib—Musculoskeletal discomfort—Doxorubicin—sarcoma	2.82e-05	0.000271	CcSEcCtD
Imatinib—Insomnia—Doxorubicin—sarcoma	2.8e-05	0.000269	CcSEcCtD
Imatinib—Paraesthesia—Doxorubicin—sarcoma	2.78e-05	0.000267	CcSEcCtD
Imatinib—Dyspnoea—Doxorubicin—sarcoma	2.76e-05	0.000265	CcSEcCtD
Imatinib—Feeling abnormal—Epirubicin—sarcoma	2.76e-05	0.000265	CcSEcCtD
Imatinib—Somnolence—Doxorubicin—sarcoma	2.75e-05	0.000264	CcSEcCtD
Imatinib—Gastrointestinal pain—Epirubicin—sarcoma	2.74e-05	0.000263	CcSEcCtD
Imatinib—Dyspepsia—Doxorubicin—sarcoma	2.73e-05	0.000262	CcSEcCtD
Imatinib—Decreased appetite—Doxorubicin—sarcoma	2.69e-05	0.000258	CcSEcCtD
Imatinib—Gastrointestinal disorder—Doxorubicin—sarcoma	2.67e-05	0.000257	CcSEcCtD
Imatinib—Fatigue—Doxorubicin—sarcoma	2.67e-05	0.000256	CcSEcCtD
Imatinib—Urticaria—Epirubicin—sarcoma	2.66e-05	0.000255	CcSEcCtD
Imatinib—Constipation—Doxorubicin—sarcoma	2.65e-05	0.000254	CcSEcCtD
Imatinib—Pain—Doxorubicin—sarcoma	2.65e-05	0.000254	CcSEcCtD
Imatinib—Abdominal pain—Epirubicin—sarcoma	2.65e-05	0.000254	CcSEcCtD
Imatinib—Body temperature increased—Epirubicin—sarcoma	2.65e-05	0.000254	CcSEcCtD
Imatinib—Feeling abnormal—Doxorubicin—sarcoma	2.55e-05	0.000245	CcSEcCtD
Imatinib—Gastrointestinal pain—Doxorubicin—sarcoma	2.53e-05	0.000243	CcSEcCtD
Imatinib—Hypersensitivity—Epirubicin—sarcoma	2.47e-05	0.000237	CcSEcCtD
Imatinib—Urticaria—Doxorubicin—sarcoma	2.46e-05	0.000236	CcSEcCtD
Imatinib—Abdominal pain—Doxorubicin—sarcoma	2.45e-05	0.000235	CcSEcCtD
Imatinib—Body temperature increased—Doxorubicin—sarcoma	2.45e-05	0.000235	CcSEcCtD
Imatinib—Asthenia—Epirubicin—sarcoma	2.4e-05	0.000231	CcSEcCtD
Imatinib—Pruritus—Epirubicin—sarcoma	2.37e-05	0.000227	CcSEcCtD
Imatinib—Diarrhoea—Epirubicin—sarcoma	2.29e-05	0.00022	CcSEcCtD
Imatinib—Hypersensitivity—Doxorubicin—sarcoma	2.28e-05	0.000219	CcSEcCtD
Imatinib—Asthenia—Doxorubicin—sarcoma	2.22e-05	0.000213	CcSEcCtD
Imatinib—Dizziness—Epirubicin—sarcoma	2.21e-05	0.000212	CcSEcCtD
Imatinib—Pruritus—Doxorubicin—sarcoma	2.19e-05	0.00021	CcSEcCtD
Imatinib—Vomiting—Epirubicin—sarcoma	2.13e-05	0.000204	CcSEcCtD
Imatinib—Diarrhoea—Doxorubicin—sarcoma	2.12e-05	0.000203	CcSEcCtD
Imatinib—Rash—Epirubicin—sarcoma	2.11e-05	0.000203	CcSEcCtD
Imatinib—Dermatitis—Epirubicin—sarcoma	2.11e-05	0.000202	CcSEcCtD
Imatinib—Headache—Epirubicin—sarcoma	2.1e-05	0.000201	CcSEcCtD
Imatinib—Dizziness—Doxorubicin—sarcoma	2.05e-05	0.000197	CcSEcCtD
Imatinib—Nausea—Epirubicin—sarcoma	1.99e-05	0.000191	CcSEcCtD
Imatinib—Vomiting—Doxorubicin—sarcoma	1.97e-05	0.000189	CcSEcCtD
Imatinib—Rash—Doxorubicin—sarcoma	1.95e-05	0.000187	CcSEcCtD
Imatinib—Dermatitis—Doxorubicin—sarcoma	1.95e-05	0.000187	CcSEcCtD
Imatinib—Headache—Doxorubicin—sarcoma	1.94e-05	0.000186	CcSEcCtD
Imatinib—Nausea—Doxorubicin—sarcoma	1.84e-05	0.000177	CcSEcCtD
Imatinib—LCK—Disease—FOXO1—sarcoma	5.92e-06	7.29e-05	CbGpPWpGaD
Imatinib—LCK—Disease—PDGFRB—sarcoma	5.91e-06	7.28e-05	CbGpPWpGaD
Imatinib—PDGFRA—Innate Immune System—KRAS—sarcoma	5.9e-06	7.27e-05	CbGpPWpGaD
Imatinib—ABL1—Developmental Biology—KRAS—sarcoma	5.87e-06	7.23e-05	CbGpPWpGaD
Imatinib—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—sarcoma	5.86e-06	7.21e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—PLCG1—sarcoma	5.84e-06	7.2e-05	CbGpPWpGaD
Imatinib—LCK—Disease—PDGFRA—sarcoma	5.82e-06	7.17e-05	CbGpPWpGaD
Imatinib—PDGFRB—Immune System—CREB1—sarcoma	5.8e-06	7.14e-05	CbGpPWpGaD
Imatinib—SLC22A1—Neuronal System—HRAS—sarcoma	5.79e-06	7.14e-05	CbGpPWpGaD
Imatinib—ABL1—Hemostasis—KRAS—sarcoma	5.75e-06	7.09e-05	CbGpPWpGaD
Imatinib—LCK—Innate Immune System—JUN—sarcoma	5.74e-06	7.07e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—FOXO1—sarcoma	5.74e-06	7.06e-05	CbGpPWpGaD
Imatinib—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—sarcoma	5.73e-06	7.06e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—PDGFRB—sarcoma	5.73e-06	7.05e-05	CbGpPWpGaD
Imatinib—LCK—Hemostasis—SRC—sarcoma	5.72e-06	7.05e-05	CbGpPWpGaD
Imatinib—CYP3A5—Metabolism—ENO2—sarcoma	5.72e-06	7.04e-05	CbGpPWpGaD
Imatinib—LCK—Innate Immune System—CTNNB1—sarcoma	5.7e-06	7.02e-05	CbGpPWpGaD
Imatinib—CYP3A5—Metabolism—HBA1—sarcoma	5.68e-06	7e-05	CbGpPWpGaD
Imatinib—PDGFRA—Adaptive Immune System—KRAS—sarcoma	5.67e-06	6.98e-05	CbGpPWpGaD
Imatinib—ABL1—Immune System—CREB1—sarcoma	5.65e-06	6.96e-05	CbGpPWpGaD
Imatinib—PDGFRB—Innate Immune System—EGFR—sarcoma	5.63e-06	6.93e-05	CbGpPWpGaD
Imatinib—KIT—Immune System—MDM2—sarcoma	5.62e-06	6.93e-05	CbGpPWpGaD
Imatinib—PDGFRB—Disease—KIT—sarcoma	5.62e-06	6.93e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—CXCR4—sarcoma	5.61e-06	6.92e-05	CbGpPWpGaD
Imatinib—LCK—Hemostasis—VEGFA—sarcoma	5.57e-06	6.87e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—ATF1—sarcoma	5.55e-06	6.84e-05	CbGpPWpGaD
Imatinib—LCK—Hemostasis—NRAS—sarcoma	5.51e-06	6.78e-05	CbGpPWpGaD
Imatinib—ABL1—Innate Immune System—EGFR—sarcoma	5.48e-06	6.75e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—IGF1R—sarcoma	5.43e-06	6.69e-05	CbGpPWpGaD
Imatinib—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—sarcoma	5.41e-06	6.66e-05	CbGpPWpGaD
Imatinib—PDGFRB—Adaptive Immune System—EGFR—sarcoma	5.4e-06	6.66e-05	CbGpPWpGaD
Imatinib—PDGFRB—Disease—CREB1—sarcoma	5.35e-06	6.59e-05	CbGpPWpGaD
Imatinib—PDGFRA—Immune System—MDM2—sarcoma	5.32e-06	6.56e-05	CbGpPWpGaD
Imatinib—PDGFRB—Innate Immune System—KRAS—sarcoma	5.32e-06	6.55e-05	CbGpPWpGaD
Imatinib—KIT—Innate Immune System—HRAS—sarcoma	5.3e-06	6.53e-05	CbGpPWpGaD
Imatinib—KIT—Disease—MDM2—sarcoma	5.19e-06	6.4e-05	CbGpPWpGaD
Imatinib—ABL1—Innate Immune System—KRAS—sarcoma	5.18e-06	6.38e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—FOXO1—sarcoma	5.17e-06	6.36e-05	CbGpPWpGaD
Imatinib—LCK—Innate Immune System—SRC—sarcoma	5.15e-06	6.35e-05	CbGpPWpGaD
Imatinib—ABL1—Hemostasis—TP53—sarcoma	5.11e-06	6.3e-05	CbGpPWpGaD
Imatinib—PDGFRB—Adaptive Immune System—KRAS—sarcoma	5.1e-06	6.29e-05	CbGpPWpGaD
Imatinib—KIT—Adaptive Immune System—HRAS—sarcoma	5.09e-06	6.27e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—PDGFRA—sarcoma	5.08e-06	6.25e-05	CbGpPWpGaD
Imatinib—KIT—Immune System—IL2—sarcoma	5.03e-06	6.19e-05	CbGpPWpGaD
Imatinib—PDGFRA—Innate Immune System—HRAS—sarcoma	5.02e-06	6.18e-05	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—KDR—sarcoma	5.01e-06	6.17e-05	CbGpPWpGaD
Imatinib—ABL1—Developmental Biology—HRAS—sarcoma	4.99e-06	6.14e-05	CbGpPWpGaD
Imatinib—NTRK1—Signaling Pathways—MDM2—sarcoma	4.96e-06	6.11e-05	CbGpPWpGaD
Imatinib—LCK—Innate Immune System—NRAS—sarcoma	4.96e-06	6.11e-05	CbGpPWpGaD
Imatinib—LCK—Adaptive Immune System—SRC—sarcoma	4.95e-06	6.09e-05	CbGpPWpGaD
Imatinib—ALB—Metabolism—ENO2—sarcoma	4.92e-06	6.07e-05	CbGpPWpGaD
Imatinib—PDGFRA—Disease—MDM2—sarcoma	4.92e-06	6.05e-05	CbGpPWpGaD
Imatinib—ALB—Metabolism—HBA1—sarcoma	4.89e-06	6.03e-05	CbGpPWpGaD
Imatinib—ABL1—Hemostasis—HRAS—sarcoma	4.89e-06	6.02e-05	CbGpPWpGaD
Imatinib—KIT—Immune System—JUN—sarcoma	4.89e-06	6.02e-05	CbGpPWpGaD
Imatinib—LCK—Immune System—KIT—sarcoma	4.89e-06	6.02e-05	CbGpPWpGaD
Imatinib—CYP3A5—Metabolism—PLCG1—sarcoma	4.85e-06	5.98e-05	CbGpPWpGaD
Imatinib—KIT—Immune System—CTNNB1—sarcoma	4.85e-06	5.98e-05	CbGpPWpGaD
Imatinib—PDGFRA—Adaptive Immune System—HRAS—sarcoma	4.82e-06	5.93e-05	CbGpPWpGaD
Imatinib—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—sarcoma	4.81e-06	5.92e-05	CbGpPWpGaD
Imatinib—PDGFRB—Immune System—MDM2—sarcoma	4.8e-06	5.91e-05	CbGpPWpGaD
Imatinib—LCK—Adaptive Immune System—NRAS—sarcoma	4.76e-06	5.86e-05	CbGpPWpGaD
Imatinib—PDGFRA—Immune System—IL2—sarcoma	4.76e-06	5.86e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—KDR—sarcoma	4.74e-06	5.84e-05	CbGpPWpGaD
Imatinib—LCK—Hemostasis—KRAS—sarcoma	4.74e-06	5.84e-05	CbGpPWpGaD
Imatinib—ABL1—Immune System—MDM2—sarcoma	4.67e-06	5.76e-05	CbGpPWpGaD
Imatinib—LCK—Immune System—CREB1—sarcoma	4.65e-06	5.73e-05	CbGpPWpGaD
Imatinib—PDGFRA—Immune System—JUN—sarcoma	4.63e-06	5.7e-05	CbGpPWpGaD
Imatinib—PDGFRA—Immune System—CTNNB1—sarcoma	4.59e-06	5.66e-05	CbGpPWpGaD
Imatinib—PDGFRB—Innate Immune System—HRAS—sarcoma	4.52e-06	5.57e-05	CbGpPWpGaD
Imatinib—LCK—Innate Immune System—EGFR—sarcoma	4.52e-06	5.56e-05	CbGpPWpGaD
Imatinib—LCK—Disease—KIT—sarcoma	4.51e-06	5.56e-05	CbGpPWpGaD
Imatinib—KIT—Disease—CTNNB1—sarcoma	4.48e-06	5.52e-05	CbGpPWpGaD
Imatinib—NTRK1—Signaling Pathways—IL2—sarcoma	4.43e-06	5.46e-05	CbGpPWpGaD
Imatinib—PDGFRB—Disease—MDM2—sarcoma	4.43e-06	5.45e-05	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—ENO2—sarcoma	4.42e-06	5.44e-05	CbGpPWpGaD
Imatinib—ABL1—Innate Immune System—HRAS—sarcoma	4.4e-06	5.42e-05	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—CREB1—sarcoma	4.39e-06	5.41e-05	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—HBA1—sarcoma	4.39e-06	5.41e-05	CbGpPWpGaD
Imatinib—KIT—Immune System—SRC—sarcoma	4.38e-06	5.4e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—KIT—sarcoma	4.37e-06	5.38e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—IGF1R—sarcoma	4.36e-06	5.37e-05	CbGpPWpGaD
Imatinib—PDGFRB—Adaptive Immune System—HRAS—sarcoma	4.34e-06	5.34e-05	CbGpPWpGaD
Imatinib—LCK—Adaptive Immune System—EGFR—sarcoma	4.34e-06	5.34e-05	CbGpPWpGaD
Imatinib—NTRK1—Signaling Pathways—CCND1—sarcoma	4.32e-06	5.32e-05	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—ENO2—sarcoma	4.31e-06	5.31e-05	CbGpPWpGaD
Imatinib—NTRK1—Signaling Pathways—JUN—sarcoma	4.31e-06	5.31e-05	CbGpPWpGaD
Imatinib—LCK—Disease—CREB1—sarcoma	4.29e-06	5.29e-05	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—HBA1—sarcoma	4.29e-06	5.28e-05	CbGpPWpGaD
Imatinib—PDGFRB—Immune System—IL2—sarcoma	4.29e-06	5.28e-05	CbGpPWpGaD
Imatinib—NTRK1—Signaling Pathways—CTNNB1—sarcoma	4.28e-06	5.27e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—KDR—sarcoma	4.27e-06	5.26e-05	CbGpPWpGaD
Imatinib—LCK—Innate Immune System—KRAS—sarcoma	4.27e-06	5.25e-05	CbGpPWpGaD
Imatinib—PDGFRA—Disease—CTNNB1—sarcoma	4.24e-06	5.22e-05	CbGpPWpGaD
Imatinib—KIT—Immune System—NRAS—sarcoma	4.22e-06	5.2e-05	CbGpPWpGaD
Imatinib—LCK—Hemostasis—TP53—sarcoma	4.21e-06	5.19e-05	CbGpPWpGaD
Imatinib—ALB—Metabolism—PLCG1—sarcoma	4.18e-06	5.15e-05	CbGpPWpGaD
Imatinib—ABL1—Immune System—IL2—sarcoma	4.18e-06	5.14e-05	CbGpPWpGaD
Imatinib—PDGFRB—Immune System—JUN—sarcoma	4.17e-06	5.13e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—CREB1—sarcoma	4.16e-06	5.12e-05	CbGpPWpGaD
Imatinib—PDGFRA—Immune System—SRC—sarcoma	4.15e-06	5.11e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—FOXO1—sarcoma	4.15e-06	5.11e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—PDGFRB—sarcoma	4.14e-06	5.1e-05	CbGpPWpGaD
Imatinib—PDGFRB—Immune System—CTNNB1—sarcoma	4.14e-06	5.1e-05	CbGpPWpGaD
Imatinib—LCK—Adaptive Immune System—KRAS—sarcoma	4.1e-06	5.05e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—PDGFRA—sarcoma	4.08e-06	5.02e-05	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—ENO2—sarcoma	4.07e-06	5.01e-05	CbGpPWpGaD
Imatinib—ABL1—Immune System—JUN—sarcoma	4.06e-06	5e-05	CbGpPWpGaD
Imatinib—KIT—Disease—SRC—sarcoma	4.05e-06	4.99e-05	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—HBA1—sarcoma	4.04e-06	4.98e-05	CbGpPWpGaD
Imatinib—ABL1—Immune System—CTNNB1—sarcoma	4.03e-06	4.97e-05	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—ENO2—sarcoma	4.03e-06	4.96e-05	CbGpPWpGaD
Imatinib—LCK—Hemostasis—HRAS—sarcoma	4.03e-06	4.96e-05	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—HBA1—sarcoma	4.01e-06	4.93e-05	CbGpPWpGaD
Imatinib—PDGFRA—Immune System—NRAS—sarcoma	3.99e-06	4.92e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—KIT—sarcoma	3.94e-06	4.85e-05	CbGpPWpGaD
Imatinib—ALB—Hemostasis—IL2—sarcoma	3.92e-06	4.83e-05	CbGpPWpGaD
Imatinib—KIT—Disease—NRAS—sarcoma	3.89e-06	4.8e-05	CbGpPWpGaD
Imatinib—NTRK1—Signaling Pathways—SRC—sarcoma	3.87e-06	4.77e-05	CbGpPWpGaD
Imatinib—LCK—Immune System—MDM2—sarcoma	3.85e-06	4.74e-05	CbGpPWpGaD
Imatinib—KIT—Immune System—EGFR—sarcoma	3.84e-06	4.73e-05	CbGpPWpGaD
Imatinib—PDGFRA—Disease—SRC—sarcoma	3.83e-06	4.72e-05	CbGpPWpGaD
Imatinib—PDGFRB—Disease—CTNNB1—sarcoma	3.82e-06	4.7e-05	CbGpPWpGaD
Imatinib—NTRK1—Signaling Pathways—VEGFA—sarcoma	3.77e-06	4.64e-05	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—PLCG1—sarcoma	3.75e-06	4.62e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—CREB1—sarcoma	3.75e-06	4.62e-05	CbGpPWpGaD
Imatinib—PDGFRB—Immune System—SRC—sarcoma	3.74e-06	4.61e-05	CbGpPWpGaD
Imatinib—NTRK1—Signaling Pathways—NRAS—sarcoma	3.72e-06	4.58e-05	CbGpPWpGaD
Imatinib—PDGFRA—Disease—NRAS—sarcoma	3.69e-06	4.54e-05	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—PLCG1—sarcoma	3.66e-06	4.51e-05	CbGpPWpGaD
Imatinib—ABL1—Immune System—SRC—sarcoma	3.64e-06	4.49e-05	CbGpPWpGaD
Imatinib—PDGFRA—Immune System—EGFR—sarcoma	3.64e-06	4.48e-05	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—MDM2—sarcoma	3.64e-06	4.48e-05	CbGpPWpGaD
Imatinib—KIT—Immune System—KRAS—sarcoma	3.63e-06	4.47e-05	CbGpPWpGaD
Imatinib—KIT—Disease—MYC—sarcoma	3.63e-06	4.47e-05	CbGpPWpGaD
Imatinib—LCK—Innate Immune System—HRAS—sarcoma	3.63e-06	4.47e-05	CbGpPWpGaD
Imatinib—PDGFRB—Immune System—NRAS—sarcoma	3.6e-06	4.43e-05	CbGpPWpGaD
Imatinib—LCK—Disease—MDM2—sarcoma	3.55e-06	4.38e-05	CbGpPWpGaD
Imatinib—KIT—Disease—EGFR—sarcoma	3.55e-06	4.37e-05	CbGpPWpGaD
Imatinib—ABL1—Immune System—NRAS—sarcoma	3.51e-06	4.32e-05	CbGpPWpGaD
Imatinib—LCK—Adaptive Immune System—HRAS—sarcoma	3.48e-06	4.29e-05	CbGpPWpGaD
Imatinib—NTRK1—Signaling Pathways—MYC—sarcoma	3.47e-06	4.27e-05	CbGpPWpGaD
Imatinib—PDGFRB—Disease—SRC—sarcoma	3.45e-06	4.25e-05	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—PLCG1—sarcoma	3.45e-06	4.25e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—ENO2—sarcoma	3.44e-06	4.24e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—MDM2—sarcoma	3.44e-06	4.24e-05	CbGpPWpGaD
Imatinib—LCK—Immune System—IL2—sarcoma	3.44e-06	4.24e-05	CbGpPWpGaD
Imatinib—PDGFRA—Immune System—KRAS—sarcoma	3.44e-06	4.23e-05	CbGpPWpGaD
Imatinib—PDGFRA—Disease—MYC—sarcoma	3.43e-06	4.23e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—KDR—sarcoma	3.43e-06	4.22e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—HBA1—sarcoma	3.42e-06	4.22e-05	CbGpPWpGaD
Imatinib—ALB—Hemostasis—SRC—sarcoma	3.42e-06	4.21e-05	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—PLCG1—sarcoma	3.42e-06	4.21e-05	CbGpPWpGaD
Imatinib—NTRK1—Signaling Pathways—EGFR—sarcoma	3.39e-06	4.18e-05	CbGpPWpGaD
Imatinib—PDGFRA—Disease—EGFR—sarcoma	3.36e-06	4.14e-05	CbGpPWpGaD
Imatinib—KIT—Disease—KRAS—sarcoma	3.35e-06	4.13e-05	CbGpPWpGaD
Imatinib—LCK—Immune System—JUN—sarcoma	3.35e-06	4.12e-05	CbGpPWpGaD
Imatinib—ALB—Hemostasis—VEGFA—sarcoma	3.33e-06	4.1e-05	CbGpPWpGaD
Imatinib—PDGFRB—Disease—NRAS—sarcoma	3.32e-06	4.09e-05	CbGpPWpGaD
Imatinib—LCK—Immune System—CTNNB1—sarcoma	3.32e-06	4.09e-05	CbGpPWpGaD
Imatinib—ALB—Hemostasis—NRAS—sarcoma	3.29e-06	4.05e-05	CbGpPWpGaD
Imatinib—PDGFRB—Immune System—EGFR—sarcoma	3.28e-06	4.04e-05	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—IL2—sarcoma	3.25e-06	4e-05	CbGpPWpGaD
Imatinib—NTRK1—Signaling Pathways—KRAS—sarcoma	3.2e-06	3.95e-05	CbGpPWpGaD
Imatinib—ABL1—Immune System—EGFR—sarcoma	3.19e-06	3.93e-05	CbGpPWpGaD
Imatinib—PDGFRA—Disease—KRAS—sarcoma	3.17e-06	3.91e-05	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—CCND1—sarcoma	3.17e-06	3.9e-05	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—JUN—sarcoma	3.16e-06	3.89e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—KIT—sarcoma	3.16e-06	3.89e-05	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—CTNNB1—sarcoma	3.14e-06	3.86e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—MDM2—sarcoma	3.1e-06	3.82e-05	CbGpPWpGaD
Imatinib—PDGFRB—Immune System—KRAS—sarcoma	3.1e-06	3.81e-05	CbGpPWpGaD
Imatinib—PDGFRB—Disease—MYC—sarcoma	3.09e-06	3.81e-05	CbGpPWpGaD
Imatinib—KIT—Immune System—HRAS—sarcoma	3.09e-06	3.8e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—IL2—sarcoma	3.08e-06	3.79e-05	CbGpPWpGaD
Imatinib—LCK—Disease—CTNNB1—sarcoma	3.07e-06	3.78e-05	CbGpPWpGaD
Imatinib—PDGFRB—Disease—EGFR—sarcoma	3.03e-06	3.73e-05	CbGpPWpGaD
Imatinib—ABL1—Immune System—KRAS—sarcoma	3.02e-06	3.72e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—CREB1—sarcoma	3.01e-06	3.7e-05	CbGpPWpGaD
Imatinib—LCK—Immune System—SRC—sarcoma	3e-06	3.7e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—CCND1—sarcoma	3e-06	3.69e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—JUN—sarcoma	2.99e-06	3.69e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—CTNNB1—sarcoma	2.97e-06	3.66e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—PLCG1—sarcoma	2.92e-06	3.6e-05	CbGpPWpGaD
Imatinib—PDGFRA—Immune System—HRAS—sarcoma	2.92e-06	3.6e-05	CbGpPWpGaD
Imatinib—LCK—Immune System—NRAS—sarcoma	2.89e-06	3.56e-05	CbGpPWpGaD
Imatinib—PDGFRB—Disease—KRAS—sarcoma	2.86e-06	3.52e-05	CbGpPWpGaD
Imatinib—KIT—Disease—HRAS—sarcoma	2.85e-06	3.51e-05	CbGpPWpGaD
Imatinib—NTRK1—Signaling Pathways—TP53—sarcoma	2.85e-06	3.51e-05	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—SRC—sarcoma	2.83e-06	3.49e-05	CbGpPWpGaD
Imatinib—ALB—Hemostasis—KRAS—sarcoma	2.83e-06	3.49e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—IL2—sarcoma	2.77e-06	3.41e-05	CbGpPWpGaD
Imatinib—LCK—Disease—SRC—sarcoma	2.77e-06	3.41e-05	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—VEGFA—sarcoma	2.76e-06	3.4e-05	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—NRAS—sarcoma	2.73e-06	3.36e-05	CbGpPWpGaD
Imatinib—NTRK1—Signaling Pathways—HRAS—sarcoma	2.72e-06	3.35e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—CCND1—sarcoma	2.7e-06	3.33e-05	CbGpPWpGaD
Imatinib—PDGFRA—Disease—HRAS—sarcoma	2.7e-06	3.32e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—JUN—sarcoma	2.7e-06	3.32e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—SRC—sarcoma	2.68e-06	3.31e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—CTNNB1—sarcoma	2.67e-06	3.29e-05	CbGpPWpGaD
Imatinib—LCK—Disease—NRAS—sarcoma	2.67e-06	3.28e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—ENO2—sarcoma	2.66e-06	3.27e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—HBA1—sarcoma	2.64e-06	3.25e-05	CbGpPWpGaD
Imatinib—PDGFRB—Immune System—HRAS—sarcoma	2.63e-06	3.24e-05	CbGpPWpGaD
Imatinib—LCK—Immune System—EGFR—sarcoma	2.63e-06	3.24e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—VEGFA—sarcoma	2.61e-06	3.22e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—NRAS—sarcoma	2.58e-06	3.18e-05	CbGpPWpGaD
Imatinib—ABL1—Immune System—HRAS—sarcoma	2.56e-06	3.16e-05	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—MYC—sarcoma	2.54e-06	3.13e-05	CbGpPWpGaD
Imatinib—ALB—Hemostasis—TP53—sarcoma	2.52e-06	3.1e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—MDM2—sarcoma	2.49e-06	3.07e-05	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—EGFR—sarcoma	2.48e-06	3.06e-05	CbGpPWpGaD
Imatinib—LCK—Immune System—KRAS—sarcoma	2.48e-06	3.06e-05	CbGpPWpGaD
Imatinib—LCK—Disease—MYC—sarcoma	2.48e-06	3.06e-05	CbGpPWpGaD
Imatinib—PDGFRB—Disease—HRAS—sarcoma	2.43e-06	2.99e-05	CbGpPWpGaD
Imatinib—LCK—Disease—EGFR—sarcoma	2.43e-06	2.99e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—SRC—sarcoma	2.42e-06	2.98e-05	CbGpPWpGaD
Imatinib—ALB—Hemostasis—HRAS—sarcoma	2.41e-06	2.97e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—MYC—sarcoma	2.4e-06	2.96e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—VEGFA—sarcoma	2.35e-06	2.9e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—EGFR—sarcoma	2.35e-06	2.9e-05	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—KRAS—sarcoma	2.35e-06	2.89e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—NRAS—sarcoma	2.33e-06	2.86e-05	CbGpPWpGaD
Imatinib—LCK—Disease—KRAS—sarcoma	2.29e-06	2.83e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—PLCG1—sarcoma	2.26e-06	2.78e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—IL2—sarcoma	2.22e-06	2.74e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—KRAS—sarcoma	2.22e-06	2.74e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—CCND1—sarcoma	2.17e-06	2.67e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—MYC—sarcoma	2.17e-06	2.67e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—JUN—sarcoma	2.16e-06	2.66e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—CTNNB1—sarcoma	2.15e-06	2.64e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—EGFR—sarcoma	2.12e-06	2.61e-05	CbGpPWpGaD
Imatinib—LCK—Immune System—HRAS—sarcoma	2.11e-06	2.6e-05	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—TP53—sarcoma	2.09e-06	2.57e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—KRAS—sarcoma	2e-06	2.47e-05	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—HRAS—sarcoma	2e-06	2.46e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—TP53—sarcoma	1.97e-06	2.43e-05	CbGpPWpGaD
Imatinib—LCK—Disease—HRAS—sarcoma	1.95e-06	2.4e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—SRC—sarcoma	1.94e-06	2.39e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—VEGFA—sarcoma	1.89e-06	2.33e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—HRAS—sarcoma	1.89e-06	2.33e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—NRAS—sarcoma	1.87e-06	2.3e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—TP53—sarcoma	1.78e-06	2.19e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—MYC—sarcoma	1.74e-06	2.14e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—HRAS—sarcoma	1.7e-06	2.1e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—EGFR—sarcoma	1.7e-06	2.09e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—KRAS—sarcoma	1.61e-06	1.98e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—TP53—sarcoma	1.43e-06	1.76e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—HRAS—sarcoma	1.37e-06	1.68e-05	CbGpPWpGaD
